NewEast Biosciences pioneered the research and development of the antibodies for GTPases and mutated Oncogene ten years ago. GTPases involve (1) signal transduction in response to activation of cell surface receptors, including transmembrane receptors such as those mediating taste, smell and vision, (2) protein biosynthesis at the ribosome, (3) regulation of cell differentiation, proliferation, division and movement, (4) translocation of proteins through membranes, (5) transport of vesicles within the cell, and vesicle-mediated secretion and uptake, through GTPase control of vesicle coat assembly. An oncogene is a gene that has the potential to cause cancer.
We offer three unique categories of antibodies, which (1) recognize only the active configuration of GTPase (not the inactive one), (2) mutated Oncogene (not mild type) and (3) have super affinity for cAMP and cGMP (no acetylation required). We have over one thousand peer reviewed articles cited our products.
$349.00
Cat.#: S219802 | ||||||
Product Name: Anti-CMTM6 Rabbit Polyclonal Antibody | ||||||
Synonyms: CKLFSF6; PRO2219 | ||||||
UNIPROT ID: Q9NX76 (Gene Accession – NP_060271 ) | ||||||
Background: CMTM6 belongs to the chemokine-like factor gene superfamily, a novel family that is similar to the chemokine and transmembrane 4 superfamilies. This gene is one of several chemokine-like factor genes located in a cluster on chromosome 3. CMTM6 is involved in the immune-related and metabolism-related pathways. It increases the expression of programmed cell death 1 ligand 1 protein, thereby impairing T cell function. Various manufactured therapeutic monoclonal antibody drugs, e.g. pembrolizumab, atezolizumab, durvalumab, nivolumab, and avelumab, bind to and inhibit the stimulation of PD-1 on CD8+ T cells by PD-L1. In effect, they block the ability of CMTMT6 to suppress PDL1/PD-1-stimulated CD8+ T-cell immune responses against tumor cells. Elevated expression of CMTM6 in glioma and head and neck squamous cell carcinoma was shown to be associated with a poor prognosis; in addition, CMTM6 is also a potential therapeutic target for triple-negative breast cancer. | ||||||
Immunogen: Synthetic peptide of human CMTM6 | ||||||
Applications: ELISA, WB, IHC | ||||||
Recommended Dilutions: IHC: 50-200;WB: 500-2000;ELISA: 5000-10000 | ||||||
Host Species: Rabbit | ||||||
Clonality: Rabbit Polyclonal | ||||||
Isotype: Immunogen-specific rabbit IgG | ||||||
Purification: Antigen affinity purification | ||||||
Species Reactivity: Human | ||||||
Constituents: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol | ||||||
Research Areas: Cell Biology, Immunology | ||||||
Storage & Shipping: Store at -20°C. Avoid repeated freezing and thawing | ||||||
|